secwatch / observer
8-K filed June 5, 2023, 7:59 PM ET ticker CMMB CIK 0001534248
leadership confidence high sentiment positive materiality 0.80

Chemomab appoints Adi Mor CEO, Sigal Fattal CFO; extends cash runway to end of 2024

Chemomab Therapeutics Ltd.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dale Pfost

Chief Executive Officer
CMMB · Chemomab Therapeutics Ltd.
Effective
2023-06-01
Successor
Adi Mor
Filed
June 5, 2023, 7:59 PM ET
In connection with his replacement as Chief Executive Officer, on June 1, 2023, Dr. Dale Pfost agreed to step down from his position on the Board, including in his capacity as Chairman of the Board, effective as of the same date.
Appointed

Adi Mor

Chief Executive Officer
CMMB · Chemomab Therapeutics Ltd.
Effective
2023-06-01
Successor
Dale Pfost
Filed
June 5, 2023, 7:59 PM ET
appointed Dr. Adi Mor, co-founder of the Company, a current class III member of the Board and the Company's Chief Scientific Officer, as Chief Executive Officer of the Company to replace Dr. Dale Pfost, effective as of the same date.
Appointed

Sigal Fattal

Chief Financial Officer
CMMB · Chemomab Therapeutics Ltd.
Effective
2023-06-01
Successor
Donald Marvin
Filed
June 5, 2023, 7:59 PM ET
the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
Departed

Donald Marvin

Chief Financial Officer
CMMB · Chemomab Therapeutics Ltd.
Effective
2023-06-01
Successor
Sigal Fattal
Filed
June 5, 2023, 7:59 PM ET
the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dale Pfost departed as Chief Executive Officer at Chemomab Therapeutics Ltd..

Action
stepped down
Role
Chief Executive Officer
Exact text from the filing
In connection with his replacement as Chief Executive Officer, on June 1, 2023, Dr. Dale Pfost agreed to step down from his position on the Board, including in his capacity as Chairman of the Board, effective as of the same date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Adi Mor was appointed as Chief Executive Officer at Chemomab Therapeutics Ltd..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
appointed Dr. Adi Mor, co-founder of the Company, a current class III member of the Board and the Company's Chief Scientific Officer, as Chief Executive Officer of the Company to replace Dr. Dale Pfost, effective as of the same date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sigal Fattal was appointed as Chief Financial Officer at Chemomab Therapeutics Ltd..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.9

Donald Marvin resigned as Chief Financial Officer at Chemomab Therapeutics Ltd..

Action
resigned
Role
Chief Financial Officer
Exact text from the filing
the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR
accession 0001178913-23-002136
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.